Shandong Ruzhi Biopharmaceutical Technology

Shandong Ruzhi Biopharmaceutical Technology is a clinical-stage biotechnology company headquartered in Jinan, China, specializing in the development of innovative small molecule drugs. The company's research focus is centered on the ubiquitin-proteasome system (UPS), a critical pathway for protein degradation and cellular homeostasis. Its lead program, RZ-001, is a highly selective inhibitor of Ubiquitin-specific protease 7 (USP7) and has entered Phase 1 clinical trials for advanced solid tumors in both China and the United States. Ruzhi Bio utilizes a structure-based drug design approach to create a pipeline of candidates targeting oncology and metabolic disorders. The firm is led by experienced scientists with a track record in global pharmaceutical R&D.